Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

@article{Becker2005FebuxostatCW,
  title={Febuxostat compared with allopurinol in patients with hyperuricemia and gout.},
  author={Michael Becker and Harold R. Schumacher and Robert L. Wortmann and Patricia A Macdonald and Denise Eustace and William A Palo and Janet Streit and Nancy Joseph-Ridge},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 23},
  pages={2450-61}
}
BACKGROUND Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. METHODS We randomly assigned 762 patients with gout and with serum urate concentrations of at least 8.0 mg per deciliter (480 micromol per liter) to receive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) once daily for 52 weeks; 760 received the study drug. Prophylaxis against gout flares with naproxen or colchicine… CONTINUE READING
Highly Influential
This paper has highly influenced 20 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 375 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

  • MA Becker, HR JrSchumacher, RL Wortmann
  • N Engl J Med
  • 2005
3 Excerpts

Management of acute and chronic gouty arthritis : present state - ofthe - art

  • RA Terkeltaub
  • Drugs
  • 2004

Metabolites of TMX - 67 , a new pharmaceutical entity for the treatment of gout or hyperuricemia , and their pharmacokinetic profiles in humans

  • S Hoshide, S Nishimura, S Ishii, N Saito, T Tanaka
  • Nucleosides Nucleotides Nucleic Acids
  • 2004

Similar Papers

Loading similar papers…